Skip to main content

Table 1 Clinical characteristics and medical treatment according to quartiles of peak C-reactive protein

From: The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction

 

Quartile of C-reactive protein, (Range mg/l)

 
 

1st (n = 85)

(0.05–5.3)

2nd (n = 82)

(5.4–19.6)

3rd (n = 84)

(19.7–64.5)

4th (n = 83)

(64.6–304)

p

Female, %

35

42

27

29

0.2

Age, mean

(range)

70

(41–91)

70

(27–90)

73

(43–97)

75

(53–92)

0.02

Waist circumference, cm (SD)

95

(12)

96

(13)

96

(12)

95

(11)

1.0

Current smokers, %

19

18

25

22

0.7

Hypertension, %

29

44

35

45

0.1

Diabetes, %

16

24

26

12

0.07

Previous AMI, %

25

30

28

25

0.8

Previous stroke, %

11

15

18

13

0.6

Previous heart failure, %

11

15

8

18

0.2

Atrial fibrillation

16

16

23

23

0.5

GFR, mean (SD)

85

(33)

84

(36)

81

(35)

66

(35)

0.004

TnT peak, median μg/L

0.49

(0.21–1.26)

1.1

(0.33–2.64)

1.9

(0.92–5.18)

4.0

(2.02–7.36)

<0.0005

LDL, mean (SD)

3.5

(1.2)

3.3

(0.9)

3.2

(0.9)

3.2

(1.3)

0.3

Clinical heart failure, during hospitalization, %

18

16

30

62

<0.0005

PCI, %

31

32

21

12

0.009

CABG, %

19

11

12

11

0.4

LMWH or warfarin in hospital, %

94

88

89

80

0.04

Aspirin, at admission, %

41

55

45

43

0.3

Clopidogrel, at discharge, %

62

61

40

16

<0.005

Statins, at discharge, %

65

68

53

42

0.004

ACE inhibitors or ARBs, at discharge, %

36

49

49

61

0.02

Betablockers, at discharge, %

89

87

87

87

0.9

Thrombolysis

11

24

26

36

0.002